共 325 条
[11]
Matas AJ(2011)Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations—twice daily Prograf® and once daily Advagraf® Brit J Clin Pharmacol 71 391-2019
[12]
Smith JM(2011)Pharmacokinetic differences corroborate observed low tacrolimus dosage in native american renal transplant patients Drug Metab Dispos 39 2017-957
[13]
Skeans MA(2011)Dosing equation for tacrolimus using genetic variants and clinical factors Brit J Clin Pharmacol 72 948-1843
[14]
Lamb KE(2012)A simultaneous D-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation J Clin Pharmacol 52 1833-115
[15]
Gustafson SK(2013)Tacrolimus population pharmacokinetics and bayesian estimation in Tunisian renal transplant recipients Int J Pharm Pharm Sci 5 108-63
[16]
Samana CJ(2013)Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients Eur J Clin Pharmacol 69 53-762
[17]
Stewart DE(2013)Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients Clin Pharmacokinet 52 751-1207
[18]
Snyder JJ(2013)Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation Transplant International 26 1198-261
[19]
Israni AK(2013)Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients Pharmacogenet Genomics 23 251-40
[20]
Kasiske BL(2014)Total plasma protein effect on tacrolimus elimination in kidney transplant patients – Population pharmacokinetic approach European Journal of Pharmaceutical Sciences 52 34-70